ArticleJournal of physiology and biochemistry2025
MicroRNA-592 suppresses breast cancer progression by targeting CYP20A1 to modulate the CHOP pathway.
Article in Journal of physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Previous studies have indicated that miR-592 may play a significant role in the development of various cancers, particularly in the proliferation and growth of breast cancer (BC) cells. However, the regulatory mechanism by which miR-592 influences apoptosis in BC cells remains unclear. In this study, functional assays investigating the role of miR-592 in apoptosis of MCF-7 cells were conducted, alongside transcriptome analysis using RNA-seq. The results demonstrate that miR-592 not only inhibits breast cancer progression but also promotes apoptosis in breast cancer cells. Several significantly dysregulated genes and enriched pathways were identified in response to miR-592 overexpression in MCF-7 cells. Among these, CYP20A1 was validated as a key target gene of miR-592, with its expression being negatively regulated by miR-592. Restoration of CYP20A1 expression reversed the pro-apoptotic and tumor-suppressive effects of miR-592 in MCF-7 cells. This process was mediated through activation of the C/EBP homologous protein (CHOP)-dependent endoplasmic reticulum stress-induced apoptotic pathway. Collectively, these findings indicate that CYP20A1 is involved in the regulation of the CHOP-mediated endoplasmic reticulum apoptosis pathway in miR-592-induced apoptosis in breast cancer cells.
Indexed as
Identifiers
41087653What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.